nach oben

Erschienen in:

01.06.2011 | Original Article

Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor

verfasst von: Tomoki Origuchi, Naoki Iwamoto, Shin-ya Kawashiri, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Kazuhiko Arima, Hideki Nakamura, Satoshi Yamasaki, Hiroaki Ida, Atsushi Kawakami, Yukitaka Ueki, Naoki Matsuoka, Munetoshi Nakashima, Akinari Mizokami, Yojiro Kawabe, Masanobu Mine, Takaaki Fukuda, Katsumi Eguchi

Erschienen in: Modern Rheumatology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

We determined the effects of etanercept on the serum concentrations of neuropeptides in RA patients. In a total of 11 patients who had been injected with etanercept, the serum levels of substance P, calcitonin gene-related peptide (CGRP), and gastrin-releasing peptide (GRP) were analyzed. Average levels of serum substance P were significantly reduced from 1.53 to 0.62 ng/ml after the injection of etanercept. In the CGRP and GRP analyses, these average levels dropped from 1.57 and 0.51 ng/ml to 0.44 and 0.04 ng/ml, respectively. Etanercept appears to decrease substance P levels with an improvement in disease activities.

Roberts LJ. New drugs for rheumatoid arthritis. N Engl J Med. 2004;351:2659–61.PubMedCrossRef

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.PubMedCrossRef

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9.PubMedCrossRef

Iwasaki A, Inoue K, Hukuda S. Distribution of neuropeptide-containing nerve fibers in the synovium and adjacent bone of the rat knee joint. Clin Exp Rheumatol. 1995;13:173–8.PubMed

Im HJ, Li X, Muddasani P, Kim GH, Davis F, Rangan J, Forsyth CB, et al. Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol. 2008;215(2):452–63.PubMedCrossRef

Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313:54–6.PubMedCrossRef

McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA. 1986;83:5731–5.PubMedCrossRef

Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304:129–35.PubMedCrossRef

Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, et al. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett. 1994;170:251–4.PubMedCrossRef

10.

Lygren I, Ostensen M, Burhol PG, Husby G. Gastrointestinal peptides in serum and synovial fluid from patients with inflammatory joint disease. Ann Rheum Dis. 1986;45:637–40.PubMedCrossRef

11.

Pert A, Moody TW, Pert CB, Dewald LA, Rivier J. Bombesin: receptor distribution in brain and effects on nociception and locomotor activity. Brain Res. 1980;193:209–20.PubMedCrossRef

12.

Okuma Y, Yokotani K, Osumi Y. Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves. Jpn J Pharmacol. 1995;68:227–30.PubMedCrossRef

13.

Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S. Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol. 2001;19:715–20.PubMed

14.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRef

15.

Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science. 1987;235:893–5.PubMedCrossRef

16.

Cerinic MM, Konttinen Y, Generini S, Cutolo M. Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol. 1998;10:220–35.PubMedCrossRef

17.

Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch Oral Biol. 1995;40:127–35.PubMedCrossRef

18.

Appelgren A, Appelgren B, Eriksson S, Kopp S, Lundeberg T, Nylander M, et al. Neuropeptides in temporomandibular joints with rheumatoid arthritis: a clinical study. Scand J Dent Res. 1991;99:519–21.PubMed

19.

Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol. 1993;32:31–5.PubMedCrossRef

20.

Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R416–26.PubMedCrossRef

21.

Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science. 1984;226:547–9.PubMedCrossRef

22.

Seegers HC, Avery PS, McWilliams DF, Haywood L, Walsh DA. Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. FASEB J. 2004;18:762–4.PubMed

23.

Zhang B, Muneta T, Yagishita K, Sekiya I. Substance P immunoreactive fibers of synovial tissue in patients with anterior cruciate ligament injury. Knee Surg Sports Traumatol Arthrosc. 2006;14:404–10.PubMedCrossRef

24.

Katz LM, Marr CM, Elliott J. Characterisation of the response of equine digital arteries and veins to substance P. J Vet Pharmacol Ther. 2003;26:361–8.PubMedCrossRef

25.

Pascual DW, Bost KL. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology. 1990;71:52–6.PubMed

26.

Sato J, Segami N, Yoshitake Y, Kaneyama K, Yoshimura H, Fujimura K, et al. Specific expression of substance P in synovial tissues of patients with symptomatic, non-reducing internal derangement of the temporomandibular joint: comparison with clinical findings. Br J Oral Maxillofac Surg. 2007;45:372–7.PubMedCrossRef

27.

Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol. 1991;20:326–35.PubMedCrossRef

28.

Sakuta H, Inaba K, Muramatsu S. Calcitonin gene-related peptide enhances cytokine-induced IL-6 production by fibroblasts. Cell Immunol. 1995;165:20–5.PubMedCrossRef

29.

Wang F, Millet I, Bottomly K, Vignery A. Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes. J Biol Chem. 1992;267:21052–7.PubMed

30.

Nong Y, Titus R, Ribeiro J, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol. 1989;143:45–9.PubMed

31.

Grimsholm O, Guo Y, Ny T, Rantapaa-Dahlqvist S, Forsgren S. Are neuropeptides important in arthritis? Studies on the importance of bombesin/GRP and substance P in a murine arthritis model. Ann N Y Acad Sci. 2007;1110:525–38.PubMedCrossRef

32.

Iannone F, Lapadula G. Neuropeptides and human osteoarthritis. J Rheumatol. 1998;25:386–8.PubMed

33.

Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241:1218–21.PubMedCrossRef

34.

Cuesta MC, Quintero L, Pons H, Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002;40:301–6.PubMedCrossRef

35.

Kane D, Lockhart JC, Balint PV, Mann C, Ferrell WR, McInnes IB. Protective effect of sensory denervation in inflammatory arthritis (evidence of regulatory neuroimmune pathways in the arthritic joint). Ann Rheum Dis. 2005;64:325–7.PubMedCrossRef

36.

Green PG. Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. Arthritis Res Ther. 2005;7:111–3.PubMedCrossRef

37.

Hernanz A, Medina S, de Miguel E, Martin-Mola E. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept. 2003;115:19–24.PubMedCrossRef

38.

Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol. 1996;71:25–30.PubMedCrossRef

Titel: Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor
verfasst von: Tomoki Origuchi
Naoki Iwamoto
Shin-ya Kawashiri
Keita Fujikawa
Toshiyuki Aramaki
Mami Tamai
Kazuhiko Arima
Hideki Nakamura
Satoshi Yamasaki
Hiroaki Ida
Atsushi Kawakami
Yukitaka Ueki
Naoki Matsuoka
Munetoshi Nakashima
Akinari Mizokami
Yojiro Kawabe
Masanobu Mine
Takaaki Fukuda
Katsumi Eguchi
Publikationsdatum: 01.06.2011
Verlag: Springer Japan
Erschienen in: Modern Rheumatology / Ausgabe 3/2011
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-010-0384-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Erratum to: A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)

The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants

Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)

Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus

Concurrent presentation of cryptococcal meningoencephalitis and systemic lupus erythematosus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin